Work

Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma

Year: 2012
Type: article
Abstract: Secondary (acquired) resistance of a tumor to a chemotherapeutic agent is characterized by regrowth of a tumor after initial shrinkage.This is distinct from primary resistance, in which a tumor never responds to treatment, a separate topic from our current study.The Smoothened (SMO) inhibitor, vismodegib (GDC-0449), has recently been shown to be useful in phase 1 and 2 clinical trials 1-3 for locally advanced basal cell carcinomas (laBCCs) (defined as inoperable owing to multiple postsurgical recurrences or incurable with surgery without significant deformity or loss of function) or meta-static BCCs (mBCCs).Collectively, laBCCs and mBCCs are termed advanced BCCs, and vismodegib treatment was approved in 2012 by the US Food and Drug Administration for this indication.Our case series describes a previously unreported phenomenon of BCC tumor re-growth within or immediately adjacent to (within 1 cm) the prior tumor bed of a vismodegib-responsive tumor while the patient is still undergoing continuous vismodegib treatment.We call this phenomenon secondary (acquired) resistance.4 MethodsWe conducted a retrospective medical chart review, approved by the Stanford human subjects panel, examining the records of 28 consequent patients with laBCC or mBCC treated with continuous administration of vismodegib and observed from 4 to 162 weeks (until any-cause death or last clinic visit).All patients were seen at Stanford Hospital and Clinics on a monthly basis.All patients had been enrolled as part of 3 vismodegib clinical trials with identical inclusion and exclusion criteria (NCT00833417, NCT00959647, and NCT01160250), including at least 1 laBCC or mBCC, and had no treatment breaks during follow-up time.Twenty-one patients were men, and 7 were women. ResultsOf treated patients, 21% developed at least 1 tumor regrowth while undergoing continuous vismodegib treatment, with a mean (SD) time to detected re-growth by clinical examination of 56.4 (52.3) weeks (Table ).The BCCs with regrowth represented 8% of all BCCs (including laBCCs, mBCCs, and nonadvanced BCCs) observed during vismodegib
Language: English
Open Access status: bronze
OpenAlex ID: W1986357982
FWCI: 5.529
Cites: 5
Cited by: 180
Related to: 10